Last reviewed · How we verify
Promius Pharma, LLC — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
6 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Desonide Cream 0.05% | Desonide Cream 0.05% | marketed | ||||
| Cloderm Cream | Cloderm Cream | marketed | Topical corticosteroid | Glucocorticoid receptor | Dermatology | |
| DFD06 Cream | DFD06 Cream | phase 3 | Topical corticosteroid | Glucocorticoid receptor | Dermatology |
Therapeutic area mix
- Dermatology · 2
- Diabetes · 1
- Multiple Sclerosis · 1
- Multiple sclerosis · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 3 shared drug classes
- Bausch & Lomb Incorporated · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 2 shared drug classes
- Astellas Pharma Inc · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- Eli Lilly and Company · 2 shared drug classes
- AO GENERIUM · 2 shared drug classes
- Hoffmann-La Roche · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Promius Pharma, LLC:
- Promius Pharma, LLC pipeline updates — RSS
- Promius Pharma, LLC pipeline updates — Atom
- Promius Pharma, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Promius Pharma, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/promius-pharma-llc. Accessed 2026-06-10.